LYEL Valuation

Lyell Immunopharma Inc

Add to Watchlist

Advanced Chart

11.320

+0.24(2.166%)1D

Overview
Forecast
Valuation
Earnings

LYEL Relative Valuation

LYEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LYEL is overvalued; if below, it's undervalued.

Historical Valuation

Lyell Immunopharma Inc (LYEL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.77. The fair price of Lyell Immunopharma Inc (LYEL) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：11.32

Fair

-0.78

Trailing

Forward

0.45

EV/EBITDA

Lyell Immunopharma Inc. (LYEL) has a current EV/EBITDA of 0.45. The 5-year average EV/EBITDA is -1.79. The thresholds are as follows: Strongly Undervalued below -9.58, Undervalued between -9.58 and -5.68, Fairly Valued between 2.11 and -5.68, Overvalued between 2.11 and 6.00, and Strongly Overvalued above 6.00. The current Forward EV/EBITDA of 0.45 falls within the Historic Trend Line -Fairly Valued range.

0.43

EV/EBIT

Lyell Immunopharma Inc. (LYEL) has a current EV/EBIT of 0.43. The 5-year average EV/EBIT is -1.69. The thresholds are as follows: Strongly Undervalued below -8.90, Undervalued between -8.90 and -5.30, Fairly Valued between 1.91 and -5.30, Overvalued between 1.91 and 5.52, and Strongly Overvalued above 5.52. The current Forward EV/EBIT of 0.43 falls within the Historic Trend Line -Fairly Valued range.

0.00

Lyell Immunopharma Inc. (LYEL) has a current PS of 0.00. The 5-year average PS is 440.49. The thresholds are as follows: Strongly Undervalued below -2267.71, Undervalued between -2267.71 and -913.61, Fairly Valued between 1794.60 and -913.61, Overvalued between 1794.60 and 3148.70, and Strongly Overvalued above 3148.70. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.41

P/OCF

Lyell Immunopharma Inc. (LYEL) has a current P/OCF of -1.41. The 5-year average P/OCF is -7.39. The thresholds are as follows: Strongly Undervalued below -19.48, Undervalued between -19.48 and -13.44, Fairly Valued between -1.35 and -13.44, Overvalued between -1.35 and 4.69, and Strongly Overvalued above 4.69. The current Forward P/OCF of -1.41 falls within the Historic Trend Line -Fairly Valued range.

-1.41

P/FCF

Lyell Immunopharma Inc. (LYEL) has a current P/FCF of -1.41. The 5-year average P/FCF is -6.81. The thresholds are as follows: Strongly Undervalued below -17.40, Undervalued between -17.40 and -12.11, Fairly Valued between -1.52 and -12.11, Overvalued between -1.52 and 3.77, and Strongly Overvalued above 3.77. The current Forward P/FCF of -1.41 falls within the Overvalued range.

Lyell Immunopharma Inc (LYEL) has a current Price-to-Book (P/B) ratio of 0.50. Compared to its 3-year average P/B ratio of 0.82 , the current P/B ratio is approximately -39.02% higher. Relative to its 5-year average P/B ratio of 1.20, the current P/B ratio is about -58.14% higher. Lyell Immunopharma Inc (LYEL) has a Forward Free Cash Flow (FCF) yield of approximately -100.03%. Compared to its 3-year average FCF yield of -47.28%, the current FCF yield is approximately 111.54% lower. Relative to its 5-year average FCF yield of -37.08% , the current FCF yield is about 169.76% lower.

0.50

P/B

Median3y

0.82

Median5y

1.20

-100.03

FCF Yield

Median3y

-47.28

Median5y

-37.08

Competitors Valuation Multiple

The average P/S ratio for LYEL's competitors is 4.87, providing a benchmark for relative valuation. Lyell Immunopharma Inc Corp (LYEL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 133.33%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LYEL.O

Lyell Immunopharma Inc

Crescent Biopharma Inc

Loss

152.82M

DMAC.O

DiaMedica Therapeutics Inc

Loss

206.70M

VYGR.O

Voyager Therapeutics Inc

Elicio Therapeutics Inc

Loss

145.09M

CRBU.O

Caribou Biosciences Inc

24.62

-3.13%

168.34M

Performance Decomposition

Market capitalization of LYEL decreased by 61.79% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.00K to 7.00K.

The secondary factor is the Margin Expansion, contributed -63.13%to the performance.

Overall, the performance of LYEL in the past 1 year is driven by Revenue Growth. Which is more sustainable.

133.33%

3.00K → 7.00K

Revenue Growth

-63.13%

-2.02M → -745.64K

Margin Expansion

-131.99%

1.45 → -0.46

P/E Change

-61.79%